SciELO - Scientific Electronic Library Online

 
vol.148 número7Hiperactividad simpática paroxística: una entidad subdiagnosticada. Caso clínico índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista médica de Chile

versión impresa ISSN 0034-9887

Resumen

QUERA, Rodrigo; FLORES, Lilian; NUNEZ, Paulina  y  IBANEZ, Patricio. Tofacitinib en el tratamiento de la colitis ulcerosa: casos clínicos. Rev. méd. Chile [online]. 2020, vol.148, n.7, pp.1039-1043. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872020000701039.

Biological therapy dramatically changed the management of Ulcerative Colitis (UC). However, a significant number of these patients fail to respond or have secondary loss of response to this strategy. In this clinical situation, the options include intensification of anti-TNF therapy, the use of a second anti-TNF or being switched to another drug class. Among the later, tofacitinib, an oral small molecule directed against the JAK/STAT pathway, is safe and effective in inducing and maintaining remission in patients with moderate-severe UC. We report two patients with UC refractory to conventional treatment and biological therapy, who responded successfully to the use of tofacitinib.

Palabras clave : Ulcerative colitis; Inflammatory Bowel Diseases; Janus Kinases; Therapeutics.

        · texto en Español     · Español ( pdf )